万维提示：
1、投稿方式：在线投稿。
2、期刊网址：
https://theoncologist.onlinelibrary.wiley.com/journal/1549490x
3、投稿网址：
http://www.editorialmanager.com/to/default.aspx
4、官网邮箱：Editors@TheOncologist.com（编辑部）
5、官网电话：(919) 680-0011
6、期刊刊期：月刊，一年出版十二期。
2021年5月20日星期四
投稿须知【官网信息】
Information for Authors
MISSION AND FOCUS
Oncology and hematology professionals are charged with continually staying on the cutting-edge of new medical treatments and technologies to foster better cancer patient care and practice management. To that end, The Oncologist is dedicated to translating the latest research developments into best multimodality practice.
Established by oncologists for oncologists, the Journal is committed to providing timely and useful information that allows physicians to excel in a challenging and ever-changing environment and to ensure their patients' rights to the highest level of care, from screening and prevention to diagnosis, treatment, and management of the disease.
Designed specifically for the busy practitioner, The Oncologist is devoted to medical and practice issues for surgical, radiation, and medical oncologists. With emphasis on clear, concise interpretation that adds value to data, the Journal aims to enhance the practice of oncology and to facilitate communication that leads to continual improvement and advancement of the field.
The Oncologist's Senior Editors believe that the various oncology subspecialists should share the same information base and read the same journal. It is up to us, as leaders in this field, to defend the patient's needs and rights and to assure that the patient has an advocate. In order to do so, we have to be united and fully informed. We pledge to put the best and latest information on cancer management before our readership, to help prepare them to do their best to improve outcomes and quality of life for all patients.
The Oncologist challenges its readers to understand what is new and better and to glimpse the future, not only in terms of research, but also in terms of new team approaches to disease management. In short, we want our readers to explore how cancer medicine could be and will be practiced now and throughout the 21st century.
DISCLAIMER
While the publisher and Editorial Board make every effort to see that no inaccurate or misleading data, opinions, or statements appear in the journal, they wish to state that the data and opinions in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the publisher, the Editorial Board, and their respective employees, officers, and agents accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement. While every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage described within this journal should be followed in conjunction with the drug manufacturer's own published literature. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. This is particularly serious if the agent to be administered is a new one or one that is infrequently used. Because of the uniqueness of each patient and the need to take into account a number of concurrent considerations, drug usage information described within the journal should be used by physicians only as a general guide to determining the best treatment for each patient.
SCOPE
The Oncologist accepts proffered manuscripts on the following topics:
Breast Cancer
Cancer Diagnostics and Molecular Pathology
Clinical Trial Results
Community Outreach
Endocrinology
Gastrointestinal Cancer
Genitourinary Cancer
Geriatric Oncology
Global Health and Cancer
Gynecologic Oncology
Head and Neck Cancers
Health Outcomes and Economics of Cancer Care
Hematologic Malignancies
Hepatobiliary Cancer
Immuno-Oncology
Lung Cancer
Medical Ethics
Melanoma and Cutaneous Malignancies
Neuro-Oncology
New Drug Development and Clinical Pharmacology
Precision Medicine Clinic: Molecular Tumor Board
Radiation Oncology
Regulatory Issues: FDA and EMA
Sarcomas
Symptom Management and Supportive Care
Submissions outside these topic categories may be considered by the Editors on a case-by-case basis.
EDITORIAL POLICIES
The Oncologist's Editorial Policies follow the recommendations of the International Committee of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), and the Committee on Publication Ethics (COPE) for guidance on policies and procedures related to publication ethics. The policies for The Oncologist have been adopted from those three advisory bodies and, where necessary, modified and tailored to meet the specific content, audiences, and aims of The Oncologist.
Submission of a manuscript is predicated on the explicit understanding that it represents original work not previously published (with the exception of abstracts) and not being considered elsewhere for publication. Further, it is understood that all authors listed on a manuscript have agreed to its submission. Authors submitting a manuscript do so with the understanding that if it is accepted for publication, the copyright, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the publisher, AlphaMed Press. It is the corresponding author's responsibility to obtain written permission to reproduce illustrations, tables, etc., from other publications.
Questions related to this policy should be directed to the editors at Editors@TheOncologist.com.
Conduct Policy
As a leading publication in the continuously evolving field of medical oncology, The Oncologist is dedicated to translating the latest research developments into best multimodality practice for physicians entrusted with cancer patient care. This mission requires ongoing, scrupulous attention to the quality and integrity of the Journal's publications, and irreproachable conduct on the part of its authors, reviewers, and Editors. In pursuit of this goal, The Oncologist has adopted a Conduct Policy that reflects and supports the Journal's unwavering commitment to the quality and integrity of work it publishes.
The Conduct Policy, found below, outlines the standards of professional behavior expected of authors, reviewers, and Editors, and addresses the Journal's policy for handling potential instances of misconduct.
For any questions or concerns regarding the Conduct Policy, please contact the editorial office for The Oncologist at Editors@TheOncologist.com.
Author Responsibilities
It is the responsibility of submitting authors to ensure that the data and work represented in their manuscript are accurately presented at the time of submission. For all submitted papers, accurate representation includes the submission of only original and unpublished material, proper acknowledgment of all author contributions, properly credited references and resources, and presentation of all relevant data and results in their true, unaltered form. The journal requires a statement disclosing any financial relationship that is relevant to the work and that might be perceived as a conflict of interest.
In addition, if manuscript content is based on scientific research, then that research is required not only to meet accepted scientific standards, but also to adhere to any applicable legal and ethical requirements regarding informed consent and standards for use of experimental animals.
Authorship & Contributions
The Oncologist adheres to the guidelines on authorship established by the International Committee of Medical Journal Editors (ICMJE) statement on Authorship and Contribution available at International Committee of Medical Journal Editors.
The corresponding author must have obtained permission from all authors for the submission of each version of the paper and for any change in authorship. Authorship should be limited to those who have contributed substantially to the work. The nature of the contribution of every author should be made clear. Each author should have participated sufficiently in the work to take public responsibility for the content.
If an article has been substantially written by a contracted writer not named in the byline, this fact needs to be noted in the Acknowledgments section of the manuscript. In addition, all other contributors who do not meet sufficient criteria for authorship should also be noted in the Acknowledgments section. Each author's contribution to the manuscript will be declared during the online submission process.
The Oncologist's conflict of interest policy requires complete transparency between the Journal's editors, the investigator-author(s), and any medical writer(s). The Journal requires identification of the medical writer(s) and clarification of their role. As part of this policy, the Journal requires that the Corresponding Author stipulate his/her principal authorship and responsibility for the content of the paper. The policy further requires that any and all correspondence from manuscript submission onward must be conducted exclusively by and between the Corresponding Author and the Journal editors.
Sponsorship
Authorship entails both accountability and independence. A submitted manuscript is the intellectual property of its authors, not the study's sponsor (e.g., a pharmaceutical company or contract research organization). The Journal will not review or publish articles based on studies that are conducted under conditions that allow the sponsor to have sole control of the data or to withhold publication. We encourage investigators to use the revised International Council of Medical Journal Editors (ICMJE) requirements on publication ethics to guide the negotiation of research contracts. Those contracts should give the researchers a substantial say in trial design, access to the raw data, responsibility for data analysis and interpretation, and the right to publish; these are the hallmarks of scholarly independence and, ultimately, academic freedom. By enforcing adherence to these requirements, we can as editors endeavor to assure our readers that the authors of an article have had a meaningful and truly independent role in the study that bears their names. The authors, therefore, will stand behind the published results, and so can the Journal.
Conflict of Interest and Financial Disclosure
Authors are required to disclose any financial relationships that may present a potential conflict of interest in the communication of nonbiased scientific information. The corresponding author is asked to make this disclosure at the time of submission; coauthors are contacted individually by the Editorial Office to secure this disclosure and their confirmation of authorship. The purpose of this disclosure is to fully inform the journal's editors, reviewers, and readers of the existence of any financial relationships that may be pertinent to the article and thus ensure full transparency of the peer-review and publication processes.
Medical writers are also required to disclose their financial relationships. A link to the medical writer form can be found here: Contribution and Disclosure for Medical Writers (PDF)
It is the policy of The Oncologist to ensure fair balance, independence, objectivity, and scientific rigor in all of its educational activities through the disclosure of financial interests and other relationships. Additionally, The Oncologist abides by the policy of the Accreditation Council for Continuing Medical Education (ACCME) stating that commercial support must be acknowledged and that all persons who affect the content of an educational activity regarding the products or services of a commercial interest must disclose any financial relationships with that commercial interest.
To this end, the corresponding author and all co-authors for each article are required by The Oncologist to complete a Potential Conflict of Interest and Financial Disclosure Form to disclose any financial commitment or obligation occurring within the last 24 months relevant to the subject matter of the article submitted. Additional relationships that might be considered competing interests, such as holding equity or paid consultancy, patent rights, etc., must also be stated. All authors will receive emails from the Editorial Office with links to the Financial Disclosure and Copyright Assignment forms once the manuscript is processed.
All information concerning potential conflicts of interest will be revealed to the peer reviewers and thereafter kept confidential (and on file by the Journal's editorial office). The Editorial Office will work with the corresponding author to formulate a disclosure statement for publication, should the manuscript be accepted. Any potential conflicts of interest found will be reviewed by the Editorial Board with the ad hoc assistance of external reviewers and resolved prior to publication.
Editors and Reviewers
Editors and reviewers are required to disclose financial interests or relationships and answer the same questions as authors. Reviewers are asked to disclose financial information when accepting a review assignment.
Defining a Conflict of Interest
A conflict of interest exists when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of an article about the product or services of that commercial interest. Nothing in this policy statement should be regarded as creating a presumption of impropriety in the existence of financial relationships. Rather, it is the purpose of this policy to inform the peer reviewers, and subsequently the readers, of the existence of financial relationships pertinent to the article in the interest of full transparency in the peer review and publication processes.
Criteria for Disclosure of Conflicts of Interest
A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients (not including providers of clinical services). Relationships with governmental agencies (e.g., the NIH), do not have to be disclosed. In addition, honoraria (or fee-for-service) or consulting funds from a Continuing Medical Education CME provider do not need to be disclosed. In addition to personal disclosure, you must disclose any financial relationships your spouse or life partner has with applicable commercial interests.
Authors who identify contracted writers should disclose the funding source. Contracted medical/science writers are also required to submit a Potential Conflict of Interest and Financial Disclosure Form, available here: Contribution and Disclosure for Medical Writers (PDF).
Misconduct
Instances involving potential author misconduct can relate to either submitted or published manuscripts. The Journal's author misconduct policy does not apply to "honest" mistakes of judgment or interpretation, which may be resolved through subsequent publication of an erratum.
Examples of potential author misconduct may include, but are not limited to, the following circumstances:
Falsifying, manipulating, or omitting data or results, images, or any other materials, processes, or content, such that the research record is not faithfully presented and preserved.
Fabricating data or results
Plagiarizing or otherwise not appropriately crediting the work of others or oneself (includes ideas, processes, words, results, etc.)
Misappropriating the data or results of others and representing them as one's own
Submitting or publishing the same, or essentially unchanged, material in more than one publication
Using published images, charts, tables, etc. without first obtaining appropriate permissions
Removing or failing to include or properly credit a contributing author or writer, including a paid professional writer.
Inappropriately assigning author status to a "guest" author or "ghostwriter" whose contributions do not meet the authorship criteria as defined by the International Committee of Medical Journal Editors (ICMJE; www.ICMJE.com); such contributions should be noted instead in the "Acknowledgments" section in the manuscript.
Failing to appropriately disclose any potential conflicts of interest (see additional information in Information for Contributors regarding The Oncologist's disclosure requirements)
Failing to abide by applicable legal and ethical standards regarding the treatment of research subjects
Potential Author Misconduct Notification and Investigation
Notification of Potential Misconduct/Response to Notifying Party
When a potential breach of conduct is brought to the Journal's attention, the Journal will contact the notifying party to acknowledge receipt of the notification. Unless the notifying party has been personally affected by the alleged misconduct, correspondence with that individual will end with the acknowledgment that notification of the concern has been received.
Potential author misconduct may also be discovered by the Journal's staff, editors, and/or reviewers, in which case the same investigative process applies.
Misconduct Notification and Investigation
Following a receipt of notification of potential author misconduct, the Journal will initiate a preliminary investigation in order to determine whether a formal investigation is warranted. In this phase of the investigation, published and submitted manuscripts, manuscript reviews, and editorial decisions will be evaluated as appropriate. Input will be sought from all individuals affected by the alleged misconduct. If the evidence found is substantial enough to warrant further investigation, then the Journal will notify the corresponding author of the manuscript in question and request a full explanation. Should the corresponding author not respond (or not respond in a timely manner) or provide an inadequate or otherwise unsatisfactory response, the Journal will contact the corresponding author's institution and/or co-authors.
If the potential misconduct involves a work published elsewhere, the Journal may also contact that publication. Should the potential misconduct involve specific scientific research, the Journal may also contact the institution where the research was conducted in order to further investigate the accuracy, authenticity, and legitimacy of the published data and results. Lastly, the Journal may also request the assistance of the U.S. Department of Health and Human Services Office of Research Integrity.
During the investigative process, the Journal will follow the guidelines and requirements outlined by the Committee on Publication Ethics (COPE) and the ICMJE to identify any misconduct and fairly gauge its severity. These references are available online at http://publicationethics.org/resources/flowcharts and at http://www.icmje.org.
Sanctions
Potential instances of author misconduct will be investigated and considered on a case-by-case basis. Should misconduct be established or admitted, the Journal will proceed with sanctions as deemed commensurate with the severity of the misconduct committed. All decisions regarding sanctions or notices of misconduct will be reviewed by the senior editorial board of The Oncologist to seek their advice and agreement with the planned action.
Sanctions are applied at the discretion of the Editor-in-Chief, the senior editorial board, and the publisher and may vary based on the severity of the misconduct and whether the manuscript in question was submitted or published.
Appropriate sanctions for author misconduct may include, but are not limited to, the following:
Publication of an erratum or Statement of Concern by the Journal Editors
Rejection of the manuscript or retraction of the publication in which the misconduct was committed
A letter of notice of sanctions to the author(s)
A letter of notice to the author's institution and/or the institution where the study was conducted
Prohibition of further submissions to or publications in the Journal by the offending author for a period of time to be determined by the Editor-in-Chief
Once the decision on sanctions has been determined, the Journal will notify the author.
……
更多详情：
https://theoncologist.onlinelibrary.wiley.com/page/journal/1549490x/homepage/for_authors
